News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Centene Corporation Reports 2012 Fourth Quarter and Full Year Results
February 5, 2013
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ST. LOUIS, Feb. 5, 2013 /PRNewswire/ -- Centene Corporation (NYSE: CNC) today announced its financial results for the quarter and year ended December 31, 2012.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Podcast
AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more
June 24, 2026
·
1 min read
·
Jef Akst
Mergers & acquisitions
Serapha takes reverse merger route to Nasdaq with $230M and gene editor from China
June 24, 2026
·
2 min read
·
Tristan Manalac
Business
Takeda enters transitional year as new CEO seeks return to growth
June 24, 2026
·
2 min read
·
Tristan Manalac
Venture capital
Ollin parlays Vabysmo beat into $330M raise to test eye disease drug in Phase 3
June 24, 2026
·
1 min read
·
Annalee Armstrong
